CRUK - Combining immunotherapies could benefit some aggressive breast cancers
Using two immunotherapy drugs together could help treat some patients with an aggressive form of breast cancer, according to an Australian study.
Researchers at Walter and Eliza Hall Institute and Peter MacCallum Cancer Centre in Melbourne found that combining the immune-boosting drugs with chemotherapy increased survival in mice with a type of breast cancer.
“The study highlights a group of patients that are most likely to benefit from drugs boosting the immune system,” said Professor Aymen Al-Shamkhani (link is external), a Cancer Research UK expert on immunotherapy from the University of Southampton.
These patients carry faults in a DNA-fixing gene known as BRCA1. The type of breast cancer is also an aggressive form known as ‘triple-negative breast cancer’ (TNBC), as the tumour cells also lack 3 different hormone-sensing molecules on their surface.
Effective treatments that specifically target these molecules in other types of breast cancer are already widely used. However, the development of such targeted therapies for TNBC has been slow.
For this latest study, scientists tested out a different approach: targeting immune-dampening molecules known as ‘checkpoints’. These normally prevent the immune system from going into overdrive. But in people with cancer they can stop immune cells from effectively attacking tumours. Drugs that block these checkpoints – called immunotherapies – release the immune system’s brakes and enhance its cancer-fighting abilities.
Looking at mice with this type of breast cancer, the researchers found that using molecules to block two different checkpoints, combined with a chemotherapy drug, boosted the animals’ immune response against the tumour. This approach also slowed down their tumour growth and improved survival. The results are published in the journal Science Translational Medicine (link is external).
“This study suggests a possible role for combining two immunotherapy drugs with chemotherapy in the treatment of some of patients with TNBC that have faulty BRCA1 genes,” said Dr Adel Samson (link is external), a Cancer Research UK immunotherapy expert from the University of Leeds.
“This is obviously welcome news, as TNBC has a poor outlook, although this treatment strategy could cause serious side effects. These treatments should therefore be first tested in carefully designed early clinical trials.”
Professor Al-Shamkhani also echoed the need for further research.
“The combination of checkpoint blockers used in this study has proven to be highly effective in the treatment of some patients with advanced melanoma,” he said. “This study therefore backs up the rationale for clinical testing of these checkpoint blockers as a treatment for these women.”
Nolan, E. et al. (2017). Combined immune checkpoint blockade as a therapeutic strategy for BRCA1-mutated breast cancer. Science Translational Medicine.
Latest News from
Age UK comments on Dispatches investigation into Bupa care homes20/06/2017 12:35:00
Age UK has commented on the Channel 4 Dispatches programme from Monday 19 June 2017, 'Bupa Care Homes Undercover'.
Care system 'buckling' says Age UK as major care homes investigation launches15/06/2017 10:35:00
A recent study into the quality of care homes which has sparked a much wider legal investigation has been called 'a manifestation of our buckling social care system' by Age UK.
Diabetes UK - Brits failing to meet the recommended daily allowance of fruit and veg13/06/2017 09:35:00
A new survey* commissioned by Diabetes UK to promote its Food you love healthy eating campaign in Diabetes Week (Sunday 11 June to Saturday 17 June), has found that 66 per cent of adults eat three or fewer portions of fruit and/or vegetables a day – well below the recommended five portions - and 46 per cent won’t eat any fruit at least three days a week.
CRUK - Two clinical trials show promise with different targeted drugs for lung cancer07/06/2017 14:10:00
Two drugs targeting different gene faults in lung cancer have shown potential to be better than those already available, according to unpublished clinical trials.
CRUK - New chemotherapy approach offers breast cancer patients a better quality of life07/06/2017 12:10:00
The chemotherapy drug capecitabine gives patients a better quality of life and is as effective at preventing breast cancer from returning as the alternative regimen called CMF, when given following epirubicin.
CRUK - Adding abiraterone to standard treatment improves prostate cancer survival by 40 per cent06/06/2017 10:35:00
Adding abiraterone to hormone therapy at the start of treatment for prostate cancer improves survival by 37 per cent, according to the results of one of the largest ever clinical trials for prostate cancer presented at the 2017 ASCO Annual Meeting in Chicago and published in the New England Journal of Medicine on Saturday.
British Red Cross - Manchester attack – What happens after05/06/2017 16:15:00
An edition of the BRC’s Newsthink encourages young people to consider ways that the public helped each other after the explosion. It also explores the role of practical help and emotional support during and after an emergency.
British Red Cross launches new UK Solidarity Fund05/06/2017 15:20:00
The British Red Cross has launched a new UK Solidarity Fund to help the victims of terror anywhere in the UK following Saturday’s attack in London.